GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx Holdings Corp. (Nasdaq: WGS) has announced the granting of 69,089 restricted stock units (RSUs) to three newly-hired employees, effective January 14, 2025. Of these, 37,497 RSUs were granted to Bryan Dechairo as part of his employment package as Chief Operating Officer. The RSUs were awarded under GeneDx's 2023 Equity Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The grants will vest in equal annual installments over four years, contingent on continued employment. Each RSU represents the right to receive one share of GeneDx's Class A Common Stock upon settlement.
GeneDx Holdings Corp. (Nasdaq: WGS) ha annunciato la concessione di 69.089 unità di azioni vincolate (RSU) a tre nuovi dipendenti, con effetto dal 14 gennaio 2025. Di queste, 37.497 RSU sono state assegnate a Bryan Dechairo come parte del suo pacchetto di assunzione in qualità di Chief Operating Officer. Le RSU sono state concesse secondo il Piano di Induzione in Capitale 2023 di GeneDx e sono conformi alla Regola di Quotazione 5635(c)(4) di Nasdaq. Le assegnazioni si acquisiranno in rate annuali uguali nel corso di quattro anni, a condizione di un'occupazione continuativa. Ogni RSU rappresenta il diritto di ricevere un'azione delle Azioni Ordinarie Classe A di GeneDx al momento della liquidazione.
GeneDx Holdings Corp. (Nasdaq: WGS) ha anunciado la concesión de 69,089 unidades de acciones restringidas (RSU) a tres nuevos empleados, a partir del 14 de enero de 2025. De estas, 37,497 RSU fueron otorgadas a Bryan Dechairo como parte de su paquete de empleo como Director de Operaciones. Las RSU se otorgaron bajo el Plan de Incentivo de Capital 2023 de GeneDx y cumplen con la Regla 5635(c)(4) de la Bolsa Nasdaq. Las concesiones se consolidarán en cuotas anuales iguales durante cuatro años, dependiendo de la continuidad del empleo. Cada RSU representa el derecho a recibir una acción de las Acciones Ordinarias Clase A de GeneDx al momento de liquidación.
GeneDx Holdings Corp. (Nasdaq: WGS)는 2025년 1월 14일부터 세 명의 신규 직원에게 69,089개의 제한 주식 단위(RSU)를 부여한다고 발표했습니다. 이 중 37,497 RSU는 최고 운영 책임자(Chief Operating Officer)인 Bryan Dechairo에게 그의 고용 패키지의 일환으로 부여되었습니다. RSU는 GeneDx의 2023년 자본 유치 계획에 따라 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다. 이 부여는 계속 고용되는 조건으로 4년에 걸쳐 동일한 연간 할부로 발생됩니다. 각 RSU는 정산 시 GeneDx의 클래스 A 보통주 한 주를 받을 권리를 나타냅니다.
GeneDx Holdings Corp. (Nasdaq: WGS) a annoncé l'octroi de 69 089 unités d'actions restreintes (RSU) à trois nouveaux employés, à compter du 14 janvier 2025. Parmi celles-ci, 37 497 RSU ont été attribuées à Bryan Dechairo dans le cadre de son paquet d'emploi en tant que Directeur des opérations. Les RSU ont été attribuées dans le cadre du Plan d'incitation en actions de GeneDx de 2023 et sont conformes à la règle d'inscription 5635(c)(4) de Nasdaq. Les attributions seront acquises par tranches annuelles égales sur quatre ans, sous réserve d'un emploi continu. Chaque RSU représente le droit de recevoir une action des actions ordinaires de classe A de GeneDx lors du règlement.
GeneDx Holdings Corp. (Nasdaq: WGS) hat die Gewährung von 69.089 beschränkten Aktieneinheiten (RSUs) an drei neu eingestellte Mitarbeiter bekannt gegeben, wirksam ab dem 14. Januar 2025. Davon erhielt 37.497 RSUs Bryan Dechairo als Teil seines Beschäftigungspakets als Chief Operating Officer. Die RSUs wurden im Rahmen des GeneDx Equity Inducement Plans 2023 gewährt und entsprechen der Nasdaq Listungsregel 5635(c)(4). Die Zuteilungen vesten in gleichen jährlichen Raten über einen Zeitraum von vier Jahren, vorausgesetzt, dass das Beschäftigungsverhältnis fortbesteht. Jede RSU stellt das Recht dar, bei der Abwicklung eine Aktie der Klasse A Stammaktien von GeneDx zu erhalten.
- Successful recruitment of new Chief Operating Officer Bryan Dechairo
- Implementation of equity-based compensation plan to attract and retain key talent
- Potential future dilution of existing shareholders due to RSU issuance
The RSUs granted to Mr. Dechairo and the two other newly-hired employees will vest in equal annual installments over a four-year period, subject to the employee’s continued service with GeneDx on each applicable vesting date. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250117189334/en/
Investor Relations:
Investors@GeneDx.com
Media:
Press@GeneDx.com
Source: GeneDx
FAQ
How many RSUs did GeneDx (WGS) grant in January 2025?
What is the vesting schedule for GeneDx's (WGS) January 2025 RSU grants?
How many RSUs were granted to GeneDx's (WGS) new Chief Operating Officer?
Under which plan were the January 2025 GeneDx (WGS) RSUs granted?
